The PD-1 and PD-L1 inhibitors competitive landscape report delivers important insights into approved as well as ongoing research of 200+ pipeline PD-1 and PD-L1 inhibitor drugs, clinical strategies, ...
Envafolimab plus docetaxel in combination with or without trilaciclib versus docetaxel in pretreated advanced or metastatic non-small cell lung cancer (NSCLC): Preliminary analysis of an open-label, ...
The findings suggest the market has progressed beyond the initial launch period for subcutaneous PD-1 therapies. Across major tumor types, physicians project continued migration toward subcutaneous ...
Association of AI-informed biomarkers of spatial organization of tumor-infiltrating lymphocytes with loco-regional recurrence in laryngeal squamous cell cancer. This is an ASCO Meeting Abstract from ...
In patients with newly diagnosed extranodal natural killer/T-cell (NK/T) lymphoma, first-line programmed death-1 (PD-1) inhibitors combined with asparaginase-based chemotherapy were associated with ...
Merck & Co.’s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer. | Merck & Co.’s almighty ...
Preliminary Phase 1 Results Of INCB161734, A Novel Oral KRAS G12D Inhibitor, In Patients With Advanced Or Metastatic Solid Tumors (Session Title: Proffered paper session: Developmental therapeutics.
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, ...
A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results